Tagged with M

Bulgaria Clinical research is one of the main areas of investment from research-based pharmaceutical companies into Bulgaria and the country is positioning itself as a clinical trials hub for the entire CEE region. Furthermore, the Bulgarian government has shown great willingness towards continuing developing this area; ensuring the growth of clinical…

Canada Michel Charbonneau, executive VP at Accord Healthcare Inc. touches upon the rapid evolution of the Canadian affiliate over the past five years, and the company’s commitment to bringing high-quality, innovative, affordable generics to patients. He furthermore expresses his hopes for collaboration between generic players in the Canadian pharmaceutical industry in…

Brazil Ricardo Lourenço, VP-Managing Director of Lupin in Brazil has been in charge of implementing the take over of Medquímica by Lupin. In this interview he explains Brazil is a land of many opportunities. He is looking forward to capitalize the fast growth rate of generic products in Brazil, revive the…

Canada Louis Pilon, president and CEO, highlights JAMP Pharma’s unique positioning as a Canadian generics company with one of the largest salesforce covering the whole Canadian market as well as the fourth-largest product portfolio, their focus on niche and complex products, their agility in seizing new opportunities, and his mission to…

Brazil Josiel Florenzano, managing director of Lundbeck Brazil and South Cone, provides us with an overview of the main dynamics shaping the Brazilian CNS market as well as the opportunities he identifies to further increase awareness and improve market access in the mental health area. You took over the helm of…

Canada Michel Lavoie, president & CEO of Dermtek Pharma in Canada, discusses the family-owned company’s track record of success over the past three decades, the emphasis they place on R&D and product development, with successful brands like Ombrelle and Reversa, and his commitment to growing Dermtek Pharma as a truly Canadian,…

EMA The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following three rounds of voting. “We are delighted, it was very tight, it was nerve-wracking, to be honest” Halbe Zijlstra, Minister…

Lithuania Rūta Pumputienė, head of the Local American Working Group (LAWG), explains the main dynamics impacting the pharmaceutical sector in general as well as the key role of the LAWG in supporting the better access to innovative treatments. Can you please introduce yourself to our international audience as well as the…

India With his over 25 years’ experience in running growing businesses and establishing start-ups, Ranjit Madan, CEO of the Life Sciences Sector Skill Development Council (LSSSDC), explains the journey of the LSSSDC and its efforts to grow the formally skilled labor force in India by involving all the stakeholders across the…

Poland Michael Kern, director general of the German Chamber of Commerce in Poland, discusses the evolving economic and business landscape in Poland and the overall impact of German companies. Furthermore, he highlights the services of the chamber and the steps that must be taken to stimulate the next influx of foreign…

Canada Dr. Reza Moridi, Minister of Research, Innovation and Science of the province of Ontario presents the impressive scope of investments undertaken within the fields of innovation and life sciences in particular over recent years. The already impressive scope of excellence in Ontario’s hospital, research and innovation, and investment landscape will…

Brazil Neide Kawabata, president of B Braun Brazil, shares B Braun’s long track record of success and commitment to Brazil, the innovations they continue to bring to the market, and the long-term vision and community support B Braun brings to its affiliates globally, as a sixth-generation family-owned company. Neide, could you…